小细胞肺癌的进展：最小公分母。 - Suppr

Suppr

超能文献

Progress in small-cell lung cancer: the lowest common denominator.

作者信息

Gandara David R, Lara Primo N, Natale Ronald, Belani Chandra

出版信息

J Clin Oncol. 2008 Sep 10;26(26):4236-8. doi: 10.1200/JCO.2008.17.2692.

DOI:10.1200/JCO.2008.17.2692

PMID:18779609

Abstract

摘要

相似文献

Progress in small-cell lung cancer: the lowest common denominator.小细胞肺癌的进展：最小公分母。

J Clin Oncol. 2008 Sep 10;26(26):4236-8. doi: 10.1200/JCO.2008.17.2692.

Clinical trials referral resource. Clinical trials in non-small-cell lung cancer.临床试验转诊资源。非小细胞肺癌的临床试验。

Oncology (Williston Park). 1999 Oct;13(10):1384, 1387-8.

[Treatment of pulmonary non-small-cell cancer--stagnation or progress?].[肺非小细胞癌的治疗——停滞还是进展？]

Ugeskr Laeger. 2001 Jun 11;163(24):3333.

Will future progress in non-small-cell lung cancer be step by step... or by leaps and bounds?非小细胞肺癌未来的进展会是循序渐进……还是会突飞猛进呢？

J Clin Oncol. 2005 Sep 1;23(25):5859-61. doi: 10.1200/JCO.2005.05.035. Epub 2005 Aug 8.

Duration of chemotherapy for metastatic non-small-cell lung cancer: more may be not better.转移性非小细胞肺癌的化疗疗程：并非越长越好。

J Clin Oncol. 2009 Dec 10;27(35):e253; author reply e254. doi: 10.1200/JCO.2009.25.1918. Epub 2009 Nov 2.

[Advanced lung cancer: progress in individualized therapy].[晚期肺癌：个体化治疗的进展]

MMW Fortschr Med. 2009 May 21;151(21):20.

CALGB 9633: an underpowered trial with a methodologically questionable conclusion.

J Clin Oncol. 2009 May 1;27(13):2300-1; author reply 2301-2. doi: 10.1200/JCO.2008.21.1565. Epub 2009 Mar 30.

Bevacizumab in non-small cell lung cancer: new indication. Too many adverse effects to justify its use.贝伐单抗用于非小细胞肺癌：新适应症。不良反应过多，使用不合理。

Prescrire Int. 2009 Feb;18(99):11.

Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.培美曲塞：新适应症。未经治疗的非小细胞肺癌：不过是另一种细胞毒性药物。并不比吉西他滨-顺铂联合用药更好，只是安全性有所不同，其他细胞毒性药物也是如此。

Prescrire Int. 2009 Jun;18(101):114.

Treatment of locally advanced non-small cell lung cancer.局部晚期非小细胞肺癌的治疗

Clin Adv Hematol Oncol. 2009 Jul;7(7):455-64, 479-80.

引用本文的文献

PACE Continuous Innovation Indicators-a novel tool to measure progress in cancer treatments.PACE持续创新指标——一种衡量癌症治疗进展的新工具。

Ecancermedicalscience. 2015 Jan 7;9:498. doi: 10.3332/ecancer.2015.498. eCollection 2015.

Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.无进展生存期与总生存期关系的建模：Ⅱ/Ⅲ 期临床试验。

Clin Cancer Res. 2013 May 15;19(10):2646-56. doi: 10.1158/1078-0432.CCR-12-2939.

Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124.广泛期小细胞肺癌中顺铂+伊立替康与顺铂+依托泊苷的3期试验的常见手臂比较结局分析：日本临床肿瘤学会9511和西南肿瘤协作组0124的最终患者水平结果

Cancer. 2010 Dec 15;116(24):5710-5. doi: 10.1002/cncr.25532. Epub 2010 Aug 24.

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.伊立替康/顺铂与依托泊苷/顺铂治疗广泛期小细胞肺癌的III期试验：SWOG S0124的临床和药物基因组学结果

J Clin Oncol. 2009 May 20;27(15):2530-5. doi: 10.1200/JCO.2008.20.1061. Epub 2009 Apr 6.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验